Arrow Greentech Is Going Ex-Dividend — That's Not Why to Own It

Arrow Greentech (NSE: ARROWGREEN) goes ex-dividend on September 15, the sort of headline that nudges a retiree to "check it out" before it's too late. Here is the honest first pass on that: the cheque is ₹5 a share, which on today's roughly ₹790 price is about 0.6%. On a stock you buy for income, that is not income — it's pocket change. So before anyone chases this ex-date, the real question is what the dividend is telling us, and whether it makes Arrow Greentech worth owning at all.

Start with the payout, because that is the part the headline highlights. The ₹5 final dividend for fiscal 2026 is tiny next to the earnings behind it. Arrow's profit for the year that ended in March came to about ₹47 crore, and the full dividend costs roughly ₹7.5 crore — a payout ratio around 15 percent, covered many times over. In income terms there is no durability question here; a payout this small is not being stretched.

That smallness is the point. Arrow has raised this final dividend four years running — ₹1, then ₹2, then ₹4, then ₹5. The payout is not funding anyone's retirement. It is a health readout. When a company sends you a token slab of profit year after year and the amount rises with earnings, the dividend tells you the business is genuinely profitable — and it tells you almost nothing about the return you can expect, because the yield is so thin.

Where the money actually comes from

Arrow isn't a sleepy packaging name even though it sits in that folder. It does make water-soluble PVA films — its Watersol brand — for agrochemical packaging, and it also runs mouth-dissolving strips. But the real money is in anti-counterfeit security products: currency threads, excise stamps, and laminates for passports and national IDs sold to sovereign customers. That security business was about 83 percent of turnover in fiscal 2025, and it runs on patents. In 2026 alone the Indian Patent Office granted Arrow 20-year patents on color-shift and graphene-based security films.

The patents are the moat, and they're genuinely valuable — statutory technology monopolies that domestic converters can't copy. But the same structure creates the risk. The profits don't come from quiet recurring soda-and-soap demand; they come whenever a government customer places an order.

A business that eats in spurts

The earnings history is a case study in why you don't buy a lumpy business off a single quarter. Fiscal 2025 was a peak: sales of ₹243 crore and profit of ₹63 crore. Fiscal 2026 slipped to ₹200 crore of sales and ₹47 crore of profit — revenue down roughly a sixth, because sovereign procurement paused. The shares fell with it, roughly halving from their highs into early 2026.

Then came the June 2026 quarter. Sales of ₹88 crore, up 111 percent from a year earlier; net profit of ₹27 crore, up 151 percent; operating margin near 41 percent. The catch is that nearly all of that quarter's revenue — about 93 percent — came from security products, one big, high-margin government batch. Absorb a fixed factory and R&D base with one large order and margins look spectacular. The shares have since climbed back near their 52-week high, around ₹790, after trading near ₹400 just months earlier.

What the income investor should actually do

The single biggest analytical trap here is taking that one quarter, multiplying it by four, and calling it a year. The June quarter produced ₹27 crore of profit; the quarter before it barely cleared ₹7 crore. This is the same lumpy business that contracted hard in fiscal 2026. So the durable question is whether the 2026 patent wins translate into a steadier, multi-year stream of security orders — or whether procurement just pauses again as it did in fiscal 2026.

For the income investor, the portfolio job is clear: Arrow Greentech is not an income holding. A 0.6 percent yield can't fund anything, and you'd be owning it for capital appreciation on a largely sovereign-dependent business that trades near its high at roughly 3.1 times book value and somewhere in the high-teens to mid-20s on trailing earnings. There is a fine quality story under the hood — debt-free, strong returns on capital, a real patent moat. But it's a bet on tender cycles and valuation, not a stream of cash flow. If you're building a yield machine, this isn't a core piece. If the security-film story genuinely appeals to you, go in knowing the ex-date tells you nothing about the return — the price and the next government order tell you everything.